Prolastin-C: payments to doctors
Payments that named Prolastin-C as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $504K
- Providers
- 600
- Transactions
- 1,611
- Average per transaction
- $313
The per-transaction average — $313 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 600 providers the average total is $841, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Grifols USA, LLC | $495,151 | 98.2% |
| Grifols Canada Ltd. | $8,684 | 1.7% |
| Grifols Shared Services North America, Inc. | $539 | 0.1% |